drugset / Trial / NCT01097707

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707

Phase 2 Terminated 414 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)

Timeline

Start
2010-04
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ERTEBEREL Small molecule 1 mg Oral
Subject ERTEBEREL Small molecule 3 mg Oral
Subject ERTEBEREL Small molecule 10 mg Oral
Subject ERTEBEREL Small molecule 25 mg Oral